News
-
Mylan has appointed John Thievon as president of its subsidiary Dey Pharma, whose products include Perforomist formoterol inhalation solution and the EasyVent valved holding chamber for MDIs. Thievon was most recently President and CEO of… Read more . . .
-
The US FDA has announced a December 12 meeting of the Psychopharmacologic Drugs Advisory Committee to discuss safety concerns related to Alexza’s Adasuve loxapine inhalation powder for the treatment of agitation associated with schizophrenia or… Read more . . .
-
Day 2 of DDL 22 started off with a focus on delivery devices, beginning with a talk by Professor Myrna Dolovich of McMaster University on selecting the correct device for patients and ending with a… Read more . . .
-
The United States Patent and Trademark Office has issued US Patent No. 8,071,127 regarding formulations of inhaled liposomal and free ciprofloxacin to Aradigm Corporation. The patent covers the company’s lead candidate, Pulmaquin dual release ciprofloxacin… Read more . . .
-
A report from research firm Decision Resources predicts no growth in the asthma drug market through 2020, in large part due to incursions by generics and greater competition. According to the company, “The overall asthma… Read more . . .
-
Merck and NanoBio will conduct preclinical studies to evaluate a vaccine combining Merck’s respiratory syncyctial virus (RSV) antigen with NanoBio’s NanoStat adjuvant. NanoBio has already conducted studies that showed the induction of immunity by a… Read more . . .
-
The prize for the best poster presented at PowderFlow 2011 was awarded to Hanne Kinnunen, a PhD student in the Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology at the University of Bath,… Read more . . .
-
Aptar Pharma launched its new DF30Plus metering valve, an extension of its DF30 line, at DDL 22. According to the company, the new valve is more compatible with a wide range of formulations, including those… Read more . . .
-
Nearly 500 people attended the first day of the 2011 Drug Delivery to the Lungs meeting (DDL 22) at the Edinburgh International Conference Centre. Approximately 50 of the DDL 22 attendees were also registered for… Read more . . .
-
Pearl Therapeutics has announced positive top-line results from a Phase 2b dose-ranging study of its PT001 glycopyrrolate (GP) MDI in patients with moderate-to-severe COPD. The randomized, double-blind study compared 4 doses of the PT001 MDI… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.